- Conditions
- Hepatic Impairment, Liver Disease, Pharmacokinetics
- Interventions
- Elafibranor
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Elafibranor, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Elafibranor, Placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Coronado, California • Colorado Springs, Colorado + 10 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 30
- States / cities
- Lancaster, California • Los Angeles, California • Sacramento, California + 26 more
- Conditions
- Non Alcoholic Steatohepatitis
- Interventions
- Elafibranor 80mg, Elafibranor 120mg
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- San Diego, California • New York, New York